TY - JOUR
T1 - Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer
AU - Fankhauser, Matthew
AU - Tan, Yuen T
AU - Macintyre, Geoff
AU - Haviv, Izhak
AU - Hong, Matthew K H
AU - Nguyen, Anne
AU - Pedersen, John S
AU - Costello, Anthony James
AU - Hovens, Christopher M
AU - Corcoran, Niall M
PY - 2014
Y1 - 2014
N2 - It has been recognized for almost a decade that concentrations of signaling androgens sufficient
to activate the androgen receptor are present in castration-resistant prostate cancer tissue. The source of these
androgens is highly controversial, with three competing models proposed. We, therefore, wished to
determine the androgenic potential of human benign and malignant (hormone-na?ve and treated) prostate
tissue when incubated with various precursors and examine concomitant changes in enzyme expression.
AB - It has been recognized for almost a decade that concentrations of signaling androgens sufficient
to activate the androgen receptor are present in castration-resistant prostate cancer tissue. The source of these
androgens is highly controversial, with three competing models proposed. We, therefore, wished to
determine the androgenic potential of human benign and malignant (hormone-na?ve and treated) prostate
tissue when incubated with various precursors and examine concomitant changes in enzyme expression.
UR - http://clincancerres.aacrjournals.org/content/20/21/5547.full.pdf
UR - https://www.scopus.com/pages/publications/84907393368
U2 - 10.1158/1078-0432.CCR-13-3483
DO - 10.1158/1078-0432.CCR-13-3483
M3 - Article
SN - 1078-0432
VL - 20
SP - 5547
EP - 5557
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 21
ER -
